Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) ROE % Adjusted to Book Value : 0.00% (As of Nov. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings ROE % Adjusted to Book Value?

Cannabis Bioscience International Holdings's ROE % for the quarter that ended in Nov. 2023 was 0.00%. Cannabis Bioscience International Holdings's PB Ratio for the quarter that ended in Nov. 2023 was N/A. Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value for the quarter that ended in Nov. 2023 was N/A.

Cannabis Bioscience International Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Bioscience International Holdings ROE % Adjusted to Book Value Chart

Cannabis Bioscience International Holdings Annual Data

Trend

Dec06

Dec07

May09

May10

May11

ROE % Adjusted to Book Value

-51.95

118.56

Cannabis Bioscience International Holdings Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	May09	Nov09	May10	Nov10	May11	Nov11	Nov22	Nov23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial							62.55	33.13	297.80	-	-

Competitive Comparison of Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value falls into.

Cannabis Bioscience International Holdings ROE % Adjusted to Book Value Calculation

Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in May. 2011 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	18.97%	/	0.16
	=	118.56%

Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value for the quarter that ended in Nov. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Cannabis Bioscience International Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036

Website

https://www.cbih.net

Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.